Fat Science

Епизоди

• Plastic Chemicals in Your Blood and What Actually Works to Remove Them 29.06.2026 50мин

  Have you ever wondered why your body holds onto weight despite your best efforts?In this eye-opening episode, Dr. Cooper reveals groundbreaking research showing that 100% of healthy adults carry at least six different plastic-related chemicals in their bodies daily. These endocrine disruptors don't just affect your hormones - they may be stored in your fat tissue and could be a hidden driver of metabolic dysfunction. The good news? New Australian research proves you can dramatically reduce these chemicals in just one week with targeted changes.KEY TAKEAWAYSEvery single person tested had at least 6 plastic chemicals in their urine, with food packaging being the primary sourceParticipants cut phthalate levels by 38-54% and BPA by 60% in just 7 days with adjustments in reducing plastic exposure in food and food packagingUltra-processed foods introduce plastic chemicals through multiple processing and packaging stepsCertain chemicals like DEHP may be stored in fat tissue and released during weight lossHeat accelerates plastic migration into food - avoid microwaving in plastic and pouring hot food into plastic containersSimple swaps like choosing fresh over canned foods and using glass containers make significant impactsThe EPA research office studying these chemicals was recently eliminated, removing key consumer protectionsNOTABLE QUOTE"People who switched to the low plastic food and kitchenware cut the phthalates excretion by 38 to 54% in one week and they cut their BPA excretion by 60% in one week." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Why Weight Loss Stalls on GLP-1s — Even When You’re Doing Everything “Right 22.06.2026 47мин

  What happens when GLP-1 medications stop working the way you hoped they would? In this mailbag episode, Dr. Emily Cooper answers listener questions about fasting, insulin levels, PCOS, lipedema, plateaus on Zepbound, and the complicated reality behind metabolic dysfunction. From the dangers of under-fueling to why individualized treatment matters so much, this conversation unpacks the science behind weight resistance with clarity and compassion.Key TakeawaysWhy fasting and restrictive eating may worsen metabolic adaptationThe real role insulin plays in metabolic healthHow PCOS and lipedema complicate weight loss treatmentWhy some people plateau on GLP-1 medications over timeThe importance of fueling, muscle preservation, and individualized careLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Normal Weight Abnormal Metabolism: Why Your Scale Doesn't Tell the Whole Story 15.06.2026 31мин

  Could you have metabolic dysfunction even at a normal weight?This episode challenges everything we've been taught about weight and health. Dr. Cooper reveals that up to 25% of normal-weight people have metabolic syndrome, yet they're rarely screened because doctors assume they're healthy based on appearance alone.KEY TAKEAWAYSWeight and metabolic health are not the same thing - you can be metabolically unhealthy at any sizeNormal weight people with metabolic dysfunction are often overlooked and undertreated by healthcare providersKey screening tests include fasting glucose, insulin, HbA1c, triglycerides, HDL cholesterol, blood pressure, and inflammatory markers like HSCRPMetabolic dysfunction can start in your 20s and take decades to develop into serious diseaseBoth normal weight and higher weight patients face bias - normal weight people aren't screened enough, while higher weight people have everything blamed on their weightEarly screening and treatment can prevent catastrophic health outcomes later in lifeThe liver plays a crucial role in metabolism and can become insulin resistant regardless of body weightNOTABLE QUOTE"You cannot tell anything about someone's health from their outside, what they look like or what, even what they're doing necessarily, but definitely not their body size. So you can be healthy or unhealthy at any size body, and I think that's what's overlooked quite a bit." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comAppendix: Key ReferencesPrimary literature supporting this episode•       Wang et al. Prevalence of Metabolically Unhealthy Normal Weight and Its Influence on the Risk of Diabetes. Journal of Clinical Endocrinology & Metabolism, 2023.•       Review: Beyond BMI — Rethinking Obesity Metrics and Cardiovascular Risk in the Era of Precision Medicine. Journal of Clinical Medicine, December 2025.•       Korean meta-analyses on metabolic dysfunction phenotypes and cardiometabolic risk, Cardiovascular and Metabolic Sciences Journal review, 2024.•       Frontiers in Nutrition, January 2026. Associations of metabolic heterogeneity with the progression of cardiometabolic multimorbidity.•       International Journal of Obesity, September 2025. Cardiovascular risk factors associated with metabolic health phenotypes.Mechanism references•       MASLD — metabolic dysfunction-associated steatotic liver disease — nomenclature and clinical framework. AASLD/EASL consensus, 2023.•       Insulin signaling, adipose tissue dysfunction, and ectopic fat deposition — reviews on the upstream-downstream relationship.•       Epicardial adipose tissue and cardiovascular dysfunction — Frontiers in Cardiovascular Medicine, January 2026.Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Mailbag: Why GLP-1 Medications Sometimes Stop Working 08.06.2026 51мин

  Have you been told your metabolism is broken and there's nothing you can do about it?This mailbag episode tackles tough questions about medication effectiveness, unexpected side effects, and the complex realities of treating metabolic dysfunction. Dr. Cooper addresses why some people regain weight while still on GLP-1s, explores the connection between hair loss and weight loss medications, and explains why leptin levels can remain stubbornly low even with proper nutrition.KEY TAKEAWAYSWeight regain while on GLP-1 medications is more common than most people realizeHair loss from weight loss medications is usually related to nutrient deficiencies, not the medication itselfLeptin dysfunction involves both hormone levels and signaling pathways throughout the bodyHypoglycemia after meals often indicates complex metabolic issues that require specialized testingStarting elderly patients on GLP-1s requires careful monitoring of nutrition, blood pressure, and side effectsMechanical eating differs from intuitive eating and remains important even when medications are workingAnnual weight loss rates of 10% or higher indicate medications are still effectiveNOTABLE QUOTE"It is not uncommon to see the weight go up while on these meds, contrary to what people think. They're great, but we always wanna point out some people don't even respond to these." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Why Three Major Obesity Organizations Just Changed What Success Means 01.06.2026 49мин

  Ever wonder why you can improve your health but still feel like you're failing because the scale isn't cooperating?Dr. Cooper breaks down groundbreaking new clinical guidelines from three major obesity organizations that are completely reframing what success in obesity treatment actually means. For the first time, these groups are saying quality of life, energy levels, and overall health matter more than the number on the scale.KEY TAKEAWAYSThree major obesity organizations worked collaboratively to issue guidelines prioritizing quality of life over weight loss as primary treatment goalsGuidelines explicitly address medical stigma as a structural barrier to care requiring systemic changeTreatment is positioned as long-term management similar to other chronic conditions like thyroid disordersDocument notably avoids calorie restriction language, focusing instead on healthy lifestyle alongside medicationSetmelanotide receives strong recommendation for rare genetic obesity conditions with available genetic testingStrong medication recommendations now include GLP-1s like semaglutide and tirzepatide, plus bupropion-naltrexone combinationNOTABLE QUOTE"Nobody ever asked. Nobody ever looked. Nobody ever said anything. I was like, 'I think there's something wrong with my metabolism or something because I'm not eating a ton.' They're like, 'Well, you must be.' And I'm like, 'N- n- no, I don't think so. I mean, unless it's happening when I'm sleeping. I don't know.'" — Andrea TaylorReference LinkAlexander L, Purnell JQ, et al. Pharmacological management of obesity in adults: a clinical guidance statement from The Obesity Society, the Obesity Medicine Association, and the Obesity Action Coalition. Obesity. 2026;34(4):851–870. doi:10.1002/oby.70164 https://onlinelibrary.wiley.com/doi/10.1002/oby.70164 Links & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• PCOS is Now PMOS: The Name Change That Changes Everything 25.05.2026 39мин

  Have you been told you have PCOS but nothing seems to help?In May 2024, after 14 years of global collaboration involving 56 organizations and 22,000 stakeholders, the medical community officially changed PCOS to PMOS - and the reason why reveals everything that's been wrong with how this condition has been understood and treated for decades. Dr. Cooper breaks down why this isn't just a name change, but a complete reframe that puts metabolic dysfunction at the center where it belongs.KEY TAKEAWAYSPCOS is now officially called PMOS - Polyendocrine Metabolic Ovarian Syndrome - shifting focus from ovarian problems to metabolic dysfunction70 million women globally are affected during reproductive years, with 70% remaining undiagnosedThe condition can occur at any weight and is driven by insulin resistance and other metabolic signals, not ovarian problemsTreatment should focus on metabolic health rather than weight loss or ovarian interventionsThe name change parallels similar shifts in medicine like MASLD replacing non-alcoholic fatty liver diseaseNOTABLE QUOTE"Most patients with this label that they've had in the past, the PCOS label, feel a sense of hopelessness, and even join support groups and things like that, and thinking that this will be a condition they have forever. And what I try to do is explain, no, this is just a physical manifestation of the metabolic disruption that we treat all the time" — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.com Fat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Mailbag - Why Your Doctor Still Believes Calories In Calories Out 18.05.2026 45мин

  Have you been told it's just calories in calories out while your lived experience says otherwise?In this mailbag episode, Dr. Cooper addresses complex metabolic questions from listeners worldwide. From eating disorders requiring specialized care to GLP-1 plateau management, each question reveals how individual biology trumps one-size-fits-all solutions.KEY TAKEAWAYSEating disorders like anorexia require comprehensive medical team treatment, not self-management approachesSide effects from GLP-1 medications often improve with consistent eating patterns and adequate nutritionThe calories in calories out model ignores the biological complexity of how your body actually burns fuelPCOS responds well to metabolic treatments because it's driven by underlying insulin and hunger hormone imbalancesSleep deprivation and chronic stress significantly impact GLP-1 effectiveness and overall metabolic functionBioidentical progesterone may help perimenopause sleep issues without the metabolic side effects of older formulationsStroke survivors may experience hypothalamic obesity that responds remarkably well to GLP-1 medicationsNOTABLE QUOTE"If that really worked, imagine, you know, would we actually need these sophisticated medications that are so groundbreaking? Would we have had decades and decades, or actually centuries of failed, you know, diet experiences by so many people?" — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• What Lipedema Really Is and Why Your Doctor Might Be Missing It 11.05.2026 48мин

  Are your legs painful to touch and resistant to weight loss despite your best efforts?Dr. Ellen Derrick, a vascular surgeon and lipedema specialist, reveals the truth about this misunderstood condition affecting 20% of women worldwide. Lipedema isn't obesity - it's a fat cell disorder where tissue responds abnormally to inflammation, creating painful, swollen areas that don't respond to traditional weight loss methods. She explains the connection between lipedema and venous insufficiency, why patients are often dismissed by doctors, and the emerging treatments offering hope.KEY TAKEAWAYSLipedema affects 20% of the female population but is routinely misdiagnosed as obesityThe condition involves abnormal fat cell response to inflammation, creating painful tissue that resists weight loss86% of lipedema patients also have venous insufficiency, creating a perfect storm of symptomsAnkle cuffs, knee pouches, and saddlebags are classic physical signs that patients often notice from pubertyGLP-1 medications like tirzepatide may help reduce inflammation and tissue tendernessLipedema reduction surgery exists but lacks insurance billing codes, making access challengingA formal medical recognition campaign is underway to establish diagnostic codes by 2026-2027NOTABLE QUOTE"The medical community really has done an outstanding job, in a way, gaslighting these patients. These patients have been aware that something is different about their body and their legs since puberty." — Dr. Ellen DerrickGUEST BIODr. Ellen Derrick is a Seattle-based board-certified vascular and general surgeon with over 20 years of clinical experience and a Master of Public Health from the University of Washington. She founded Boxbar Vascular, specializing in lipedema and related metabolic conditions, and serves on the board of the Lipedema Society working toward formal medical recognition of the condition.Links & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Metabolic Breaking News: 3 Developments You Should Know About 07.05.2026 8мин

  Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down three breaking metabolic health stories in this quick bonus episode — from a newly approved oral GLP-1 to a major price drop for Medicare patients.Links & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Mailbag: Mechanical Eating vs Calorie Counting on Ozempic and Wegovy 04.05.2026 44мин

  Have you ever wondered if you should get liposuction when you need skin removal surgery after major weight loss?In this mailbag episode, Dr. Cooper, Mark, and Andrea tackle questions from listeners around the world, from Germany to Alabama to Chicago. They discuss why restricting calories while on GLP-1 medications can actually work against you, address the reality of finding metabolic-informed doctors internationally, and explain the science behind fat cell removal during skin surgeries. Plus, they share details about the newly approved oral GLP-1 medication orforglipron (Foundayo) and why vegetables, fats and starches matter even when you're protein-focused.KEY TAKEAWAYSRestricting calories on GLP-1 medications can lower your metabolic rate and weaken your body's natural GLP-1 productionLiposuction during skin removal surgery may disrupt leptin signaling, though males may be less affected than females due to naturally lower leptin levelsFinding metabolic-informed doctors globally remains challenging, but obesity medicine certification and Canadian and European obesity organizations may offer better resourcesThe oral GLP-1 medication orforglipron will likely be less expensive but also less effective than dual-agonist medications like tirzepatideMechanical eating without calorie counting often produces better long-term results than restrictive approachesVegetables provide essential micronutrients and support healthy microbiome function that protein alone cannot replaceMajor weight loss surgery like tummy tucks is serious surgery that requires careful consideration and qualified surgeonsNOTE: This episode was recorded before Foundayo (orforglipron) was released on the market. The price is the same as the Wegovy pill. Listen to our episode - “New Obesity Drugs” for more information https://podcasts.apple.com/us/podcast/fat-science/id1715377331?i=1000762362056NOTABLE QUOTE"If only they didn't fall into that diet cycle, some of them, their weight would be a hundred pounds less. Yes, it might be still elevated, but a large chunk of that weight was caused by the diet cycle itself." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Top 10 GLP-1 Myths Debunked by Science 27.04.2026 33мин

  Ever hear someone say GLP-1 medications cause osteoporosis or make your hair fall out?This episode tackles the top 10 biggest myths about GLP-1 medications flooding social media and separates the science from the scary headlines. Dr. Cooper breaks down what's actually happening in your body versus what the internet claims, from bone density concerns to the dreaded "Ozempic face."KEY TAKEAWAYS·  GLP-1 medications don't cause osteoporosis - inadequate nutrition while losing weight can weaken bones·  Hair loss is typically from nutritional deficits, not the medication itself·  These drugs slow gastric emptying but don't cause permanent stomach paralysis·  Weight regain after stopping is expected since you're treating a chronic medical condition·  Muscle loss comes from eating too little, not from the medication directly·  The thyroid cancer warning comes from rodent studies and hasn't been observed in humans·  GLP-1s actually protect the pancreas rather than damage itNOTABLE QUOTE"Metabolic dysfunction is biological, it's not something within your means to correct just through lifestyle strategies." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• New Obesity Drugs: What's FDA Approved and What's Coming 20.04.2026 47мин

  The obesity medication landscape just changed — again. One brand-new pill is already in pharmacies, and five more are in various stages of approval. But the real story isn't the drugs themselves: it's what they're revealing about how your metabolism actually works, and why willpower was never the problem.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down six metabolic medications — two newly FDA-approved and four in the pipeline — covering everything from a flexible new oral GLP-1 pill to drugs that target the brain's central metabolic pathway directly. Dr. Cooper explains the science behind each one, who might benefit, and what the pipeline tells us about the future of metabolic care. This is the most comprehensive drug update the show has done, and it arrives at a moment when the field is moving faster than ever.Key TakeawaysFoundayo (orforglipron), approved April 1st, is the first small molecule oral GLP-1 — no empty stomach requirement, no cold chain, and potentially lower production costs long-term.The amylin hormone may uniquely address both "I'm nourished" and "I weigh enough" signals in the brain — making the amylin pathway a powerful and underutilized target.Retatrutide (Lilly's triple agonist targeting GLP-1, GIP, and glucagon receptors) is showing unprecedented effectiveness plus significant non-scale benefits, including fatty liver reduction — but is still years from approval.The brain's melanocortin 4 receptor is the CEO of metabolism — regulating energy expenditure, appetite, and insulin — and new drugs targeting it represent the deepest intervention yet.Many of these medications are showing weight-independent benefits, including improvements in kidney, liver, cardiovascular risk, sleep apnea, and joint health that have nothing to do with how much weight is lost.Notable Quote"Everybody focuses on appetite, and you just need to eat less. But now with these medications and how they actually affect our biology, it becomes very clear that there's so much more to this." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Mailbag: Understanding Insulin Resistance Testing and GLP-1 Medication Side Effects 13.04.2026 39мин

  Have you been told insulin resistance testing doesn't exist or wondered if you're increasing your GLP-1 dose too quickly?Dr. Cooper, Andrea, and Mark tackle listener questions from around the world, addressing common concerns about insulin resistance testing availability, managing severe GI side effects from higher doses, interpreting DEXA scan results, and developing sustainable maintenance strategies. They discuss the difference between hunger and food noise, explain why winter illness might stall weight loss, and share insights about visceral fat concerns even at normal weight.KEY TAKEAWAYSInsulin resistance can be tested through fasting insulin and glucose ratios, even in countries where insulin testing is less commonRapid weight loss rates above 15% annually may indicate no need for dose increasesSevere GI side effects warrant investigation beyond medication adjustment, including gallbladder evaluationDEXA scans provide valuable visceral fat measurements, but results should be interpreted alongside overall health markersMaintenance strategies should focus on nutritional stability before considering medication taperingNOTABLE QUOTE"It's not that the medicine causes the rebound weight gain, it's that with the medication in there, the body is getting better signals, and then you go and take the medication away and you're in the same boat." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Navigating the GLP-1 Wild West: A Conversation With Dr. Vin Gupta 06.04.2026 1ч 2мин

  Are you getting a GLP-1 prescription from someone who's never examined you?Dr. Vin Gupta, pulmonologist and former Chief Medical Officer at Amazon, joins Dr. Cooper to expose the dangerous gap between legitimate obesity medicine and the unregulated direct-to-consumer market. This conversation reveals why proper medical evaluation matters and how profit-driven platforms are exploiting desperate patients.KEY TAKEAWAYSGLP-1 medications require individualized medical evaluation, not one-size-fits-all prescribingDirect-to-consumer microdosing platforms lack FDA approval and proper medical oversightThe erosion of trust in healthcare has created opportunities for unregulated treatmentsComprehensive metabolic care includes regular lab work, body composition monitoring, and personalized treatment plansTechnology should enhance medical care, not replace proper physician evaluationNOTABLE QUOTE"I see so many people that come in, you know, they're obsessed with monitoring their HRV, their heart rate variability, and yet they had no idea they have pre-diabetes and they had no idea that they have triglyceride levels through the roof." — Dr. Emily CooperGUEST BIODr. Vin Gupta is a pulmonologist, public health expert, and medical analyst for NBC News. He served as Chief Medical Officer at Amazon and has dedicated his career to translating complex science into actionable health insights at both individual and population levels.GLOSSARYGLP-1 medications: Glucagon-like peptide-1 receptor agonists, medications that help regulate blood sugar and appetite, including brand names like Ozempic, Wegovy, and ZepboundMicrodosing: Taking smaller amounts of medication than officially prescribed or approvedDirect-to-consumer (D2C): Healthcare services that bypass traditional medical settings, often delivered through apps or online platformsHRV: Heart rate variability, a measurement of the variation in time between heartbeatsPre-diabetes: Blood sugar levels that are higher than normal but not high enough to be diagnosed as type 2 diabetesLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• What Happens to Your Body When You Stop Taking GLP-1s 30.03.2026 47мин

  What really happens when you stop GLP-1 medications — and are the headlines telling you the whole story? The answer is more nuanced than social media wants you to believe.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor break down four recent studies on GLP-1 treatment outcomes, weight regain, and a groundbreaking new drug that could preserve lean mass during treatment. They walk through the methodology behind each paper, explain why two studies asking the same question got opposite answers, and reveal what a new monoclonal antibody called bimagrumab could mean for the future of metabolic treatment.Key TakeawaysWhen you stop treating any chronic metabolic condition, the condition returns — that's not failure, that's biology.Real-world data showed 56% of people who stopped filling GLP-1 prescriptions maintained or continued losing weight — likely because they continued working with their clinician on alternative treatments.A new monoclonal antibody called bimagrumab showed 11% body weight reduction on its own, while simultaneously increasing lean mass by 3% — without affecting appetite.When combined with semaglutide, bimagrumab reduced lean mass loss from 28% to just 11% of total weight lost.Not eating enough while on GLP-1s drives greater lean mass loss — nutrition is still the best tool for preserving muscle.Notable Quote"It wasn't my failure and it was disease underneath everything. Finding that out — that it wasn't my fault — that was the miracle of the whole process to me." — Andrea TaylorLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations
• Mailbag: Fasting, Food Noise & GLP-1s 23.03.2026 44мин

  Ever wonder why fasting worked at first — then stopped? Or why you lost 80 pounds only to gain back 100?In this mailbag episode, Dr. Emily Cooper, Mark Wright, and Andrea Taylor tackle the most misunderstood topics in metabolic health. From the harsh reality of fasting culture to the surprising metabolic challenges faced by normal-weight individuals, this conversation validates what you've been experiencing and explains the science behind it. You'll also hear why GLP-1 medications aren't just weight loss drugs, why your body might be fighting you even when you're doing everything right, and what happens when your job — like shift work or firefighting — disrupts your metabolism for years.KEY TAKEAWAYSYou can have metabolic dysfunction at a normal weight with what appear to be normal labs, for example, when insulin is over suppressed from chronic under-fueling or overexercisingFasting triggers the same biological adaptation as any restrictive diet and typically results in weight regain that's 22 percent higher than starting weightFood noise is biological, not psychological, and stems from an imbalance of hormones and neurotransmitters signaling nutritional insecurityGLP-1 medications may improve immune function because metabolic health and immunity are deeply connectedShift work and chronic sleep disruption can cause real metabolic damage by weakening leptin signals, increasing insulin resistance, and amplifying hunger hormonesNOTABLE QUOTE"You can't trick your body. You have to have that foundational fueling in there." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Why You Keep Waking Up at Night — What 15,000 Patient Encounters Reveal About Sleep and Metabolism 16.03.2026 49мин

  Are you getting eight hours in bed but still waking up exhausted?Dr. Emily Cooper shares groundbreaking findings from nearly 15,000 patient encounters at her metabolic clinic. The data reveals surprising connections between stress, eating frequency, sleep quality, and metabolic health — and why the number of hours you spend in bed doesn't tell the whole story.KEY TAKEAWAYSOver 60% of patients reported trouble staying asleep, even when they got eight hours in bedHigher stress levels were associated with double the rate of low energy and significantly worse sleep qualityEating frequency matters — patients eating five times per day reported the best sleep and highest energy levelsThe sweet spot between meals is two to four hours — longer gaps were linked to sleep disruption and low energyAny amount of alcohol was associated with fragmented sleep, regardless of stress levelsNearly 65% of patients were not hydrating adequately throughout the dayNOTABLE QUOTE"If your cortisol goes high, we can get the same effects that happen when we take steroids, which we know promote pre-diabetes, insulin resistance, weight gain." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Mailbag: Your GLP-1 Questions: Hair Loss, Blood Sugar Spikes & Hormone Therapy 09.03.2026 50мин

  Think squashing your post-meal glucose spike is the healthy thing to do? What if that flat line on your CGM is actually telling your brain you didn't eat — and slowing your metabolism as a result?This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor open the mailbag to tackle listener questions from around the world — Australia, New Zealand, and across the U.S. They dig into hormone replacement therapy and metabolism, why your GLP-1 medication might be causing hair loss, what a normal blood sugar response actually looks like, and how lipedema differs from obesity. Dr. Cooper also revisits metabolic syndrome and why it's not outdated — just underutilized.Key TakeawaysHormone replacement therapy isn't a reliable tool for improving metabolism — it's better suited for symptom relief and bone health in specific situations.Progesterone, which must accompany estrogen if you still have your uterus, can actually disrupt metabolism in some women — acting almost like a steroid.A flat glucose line after eating isn't the goal — your brain needs to see glucose go up to register that you've been nourished and keep your metabolism running.Hair loss on GLP-1 medications is more likely tied to nutrient deficiencies (especially iron and protein) than the drugs themselves.Lipedema is a disease of the fat tissue itself — separate from obesity — and tirzepatide may help reduce the inflammatory symptoms even though it won't eliminate the fat deposits.Notable Quote"If your glucose is flat line, your brain's not very convinced that you ate much — and then you're not getting the metabolic benefit." — Dr. Emily CooperLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• Why GLP-1s Alone May Not Be Enough: A Listener's Real Story 02.03.2026 56мин

  What happens when you do everything "right" — the GLP-1, the protein shake, the tracking — and the scale still won't budge? This episode reveals why doing everything “right” might actually be a big part of the problem.This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor welcome Sandy, a listener from Pennsylvania who has been on the metabolic health journey for over a year. Sandy's story is one many listeners will recognize: decades of dieting starting in childhood, a body that kept adapting against her, and a medical system that kept telling her to try harder. But when Dr. Cooper reviews Sandy's actual lab work live on air, what she finds reframes everything — and offers a path forward that has nothing to do with restriction.Key TakeawaysSuppressed leptin hides a portion of your body fat from your brain, and possibly signals your brain that you're underweight — so your brain fights weight loss even when your body doesn't need protecting.Low insulin isn't always healthy; it can be a sign of the "selfish brain" redirecting precious glucose to the brain at the expense of your muscles.Weight cycling — losing and regaining the same weight repeatedly — creates cardiovascular and metabolic risk.Mechanical eating is the antidote to disordered eating: structured, non-restrictive fueling that rebuilds metabolic trust.GLP-1 medications can suppress appetite, so under-eating becomes a real risk — especially for people already conditioned to restrict.The goal isn't the number on the scale. It's metabolic stability and metabolic health, and those things are not the same.Notable Quote"It was such a revelation to me to hear you guys talk about it — it's a metabolic disorder. It's not a willpower issue, it's not a personal failing. It's something absolutely beyond my control. Like diabetes would be. Like migraines would be." — SandyLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.
• The Science Behind the New Wegovy Pill: One-On-One with Novo Nordisk’s Dr. Jason Brett. 23.02.2026 1ч

  The Science Behind the New Wegovy Pill (with Novo Nordisk’s Dr. Jason Brett)What actually makes a GLP-1 pill work in the real world—and why does taking it come with such specific rules? And if these meds improve health beyond weight, why does the conversation still get stuck on the scale?This week on Fat Science, Dr. Emily Cooper, Mark Wright, and Andrea Taylor are joined by Dr. Jason Brett of Novo Nordisk to break down the science behind the newly approved Wegovy pill. They talk about what it takes to deliver a peptide medication orally, what the dosing and day-to-day routine really look like, and why access and pricing remain such a big part of the story. The conversation also zooms out to the bigger point: treating obesity is about improving health outcomes—like liver and cardiovascular risk—not just weight.Key TakeawaysOral semaglutide requires specific formulation technology to survive the stomach and be absorbed at a meaningful level.The “30-minute rule” isn’t random—it’s part of how the pill has a chance to work as intended.Treating obesity is about improving health outcomes (like liver and heart risk), not just “moving a number on a scale.”Pricing and access shape who can actually benefit, even when the science is strong.Calorie-restriction messaging can backfire for people already dealing with metabolic adaptation and under-nutrition.Notable Quote"Fat Science has no financial relationship with Novo Nordisk. No sponsorship. No consulting fees, no affiliate arrangements. Zero." — Mark WrightLinks & ResourcesPodcast Home: fatsciencepodcast.comCooper Center for Metabolism: coopermetabolic.comResources from Dr. Cooper: coopermetabolic.com/resourcesJoin Our Community: patreon.com/cw/FatSciencePodcastSubmit Your Question: questions@fatsciencepodcast.com or dr.c@fatsciencepodcast.comFat Science is supported by the Diabesity Institute, a nonprofit dedicated to increasing access to effective, science-based metabolic care.Disclaimer: This podcast is for informational purposes only and is not intended as medical advice. Please consult with a qualified healthcare provider for personalized recommendations.